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The ABCA1 protein mediates the transfer of cellular
cholesterol across the plasmamembrane to apolipo-
protein A-I. Loss-of-functionmutations in the ABCA1
gene induce Tangier disease and familial hypoalpha-
lipoproteinemia, both cardiovascular conditions
characterized by abnormally low levels of serum
cholesterol, increased cholesterol in macrophages,
and subsequent formation of vascular plaque.
Increased intracellular cholesterol levels are also
frequently found in cancer cells. Here, we demon-
strate anticancer activity of ABCA1 efflux function,
which is compromised following inhibition of
ABCA1 gene expression by oncogenic mutations or
cancer-specific ABCA1 loss-of-function mutations.
In concert with elevated cholesterol synthesis
found in cancer cells, ABCA1 deficiency allows for
increased mitochondrial cholesterol, inhibits release
of mitochondrial cell death-promoting molecules,
and thus facilitates cancer cell survival, suggesting
that elevated mitochondrial cholesterol is essential
to the cancer phenotype.
INTRODUCTION
Current interest in cancer cell metabolism originates from
several recent discoveries indicating that elevated glycolytic
activity found in various types of cancer, commonly known as
the Warburg effect (Warburg, 1930), is an essential feature of
the cancer phenotype (Christofk et al., 2008; Fantin et al.,
2006;Weinberg et al., 2010). Similarly, a causal role for increased
cholesterol in malignant cell transformation has long been
debated, perhaps first suggested by work in the early 20th
century indicating accelerated tumor growth following choles-
terol injection into xenografts (Robertson and Burnett, 1913).
Genetic evidence for a causal link between multistep oncogen-
esis and the control of cholesterol homeostasis, however, has
ever been lacking.
Aberrant regulation of cholesterol homeostasis has been asso-
ciated with multiple types of cancer. Numerous studies have
shown increased levels of cholesterol in tumors as compared
to normal tissue (Dessı´ et al., 1992, 1994; Kolanjiappan et al.,
2003; Rudling and Collins, 1996; Schaffner, 1981; Yoshioka580 Cell Reports 2, 580–590, September 27, 2012 ª2012 The Authoret al., 2000). Moreover, low serum cholesterol levels have been
associated with tumor presence in cancer patients, suggesting
cholesterol may accumulate in tumor tissue (Benn et al., 2011;
Jacobs et al., 1992; Strasak et al., 2009). Multiple paths to in-
creasing intracellular cholesterol have been observed in cancer
cells. These include upregulation of 3-hydroxy-3-methylglutaryl
CoA reductase (HMG-CoAR) activity, the rate-limiting step of
the cholesterol synthesis pathway (Caruso et al., 1999, 2002;
Notarnicola et al., 2004), loss of feedback inhibition of HMG-
CoAR by cholesterol (Gregg et al., 1986; Hentosh et al., 2001;
Siperstein, 1995), increased uptake of extracellular cholesterol
through the low-density lipoprotein receptor (Graziani et al.,
2002; Schimanski et al., 2009; Tatidis et al., 2002), and
decreased expression of the cholesterol exporter termed ATP
binding cassette transporter A1 (ABCA1) (Basso et al., 2005; Ki
et al., 2007; Moustafa et al., 2004; Schimanski et al., 2009), all
together suggesting that cholesterol levels in cancer cells can
be modulated by any of these interconnected processes.
In vivo evidence to support a cancer-promoting role of
cholesterol is limited to pharmacological approaches. Various
statins, which inhibit cholesterol synthesis by blocking activity
of HMG-CoAR, have been shown to reduce tumor growth
in xenograft models (Gao et al., 2010; Huang et al., 2010;
Kochuparambil et al., 2011). Moreover, pharmacological
inhibition of squalene synthase, the first committed step in
cholesterol synthesis, lowered resistance to the chemothera-
peutic agent doxorubicin in a xenograft model of liver cancer,
albeit without significant effect on tumor growth, when used on
its own (Montero et al., 2008). Furthermore, liver X receptor
(LXR) agonists, which are known to induce ABCA1 expression,
inhibited tumor growth and progression to androgen indepen-
dence in a xenograft model of prostate cancer (Chuu et al.,
2006). The antitumor effects of these compounds, however,
may involve a variety of mechanisms, as for example, statins
inhibit GTPases such as Ras and Rho family proteins via block-
ing protein prenylation and/or farnesylation (Demierre et al.,
2005) and LXR agonists induce cell cycle arrest through upregu-
lation of p27 (Chuu and Lin, 2010).
Efforts to identify causal relationships between oncogenic
mutations and associatedmetabolic or cholesterol dysregulation
have been limited, presumably for two reasons: (1) most cancer
mutations have been identified in genes regulating cellular
signaling pathways (Pickeral et al., 2000), and (2) analysis of
regulatory processes downstream of oncogenic mutations has
been difficult due to the complexity of change associated with
malignant transformation. Only recently have several genetics
approaches been developed readily capable of identifying non-
mutant genes essential to cell transformation (nonmutant drivers)
(Luo et al., 2009; McMurray et al., 2008; Schlabach et al., 2008;
Shaffer et al., 2008; Zender et al., 2008).We developed a strategy
to identify such genes based on the notion that malignant cell
transformation is a highly cooperative process (Hahn et al.,
1999; Land et al., 1983) and involves synergistic regulation of
nonmutant genes and proteins downstream of oncogenic muta-
tions (Lloyd et al., 1997; Sewing et al., 1997; Xia and Land, 2007).
In fact, we were able to demonstrate that genes regulated syner-
gistically by multiple cancer gene mutations, i.e., ‘‘cooperation
response genes’’ (CRGs), are highly enriched for nonmutant
drivers of the cancer phenotype (McMurray et al., 2008). Notably,
CRGs contain a large fraction of genes involved in the control of
cell metabolism (McMurray et al., 2008), thus pinpointing poten-
tial causal linkages between oncogenic mutations and the regu-
lation of cancer cell metabolism.
The presence among CRGs of the ATP-binding cassette
transporter A1/cholesterol exporter (Abca1) gene, a key player
in cholesterol metabolism, prompted us to investigate the role
of ABCA1 in regulating both intracellular cholesterol levels and
the cancer phenotype. The ABCA1 protein mediates the transfer
of cellular cholesterol across the plasma membrane to apolipo-
protein A-I (ApoAI), the major apolipoprotein component of
high-density lipoprotein (HDL) (Attie, 2007). Loss-of-function
mutations in the ABCA1 gene induce Tangier disease (TD) and
familial hypoalphalipoproteinemia, both cardiovascular condi-
tions characterized by abnormally low levels of HDL-bound
serum cholesterol and excess cholesterol in macrophages fol-
lowed by vascular plaque (Singaraja et al., 2006). Based on our
previous identification of Abca1 as a synergistically downregu-
lated CRG (McMurray et al., 2008) and its well-characterized
function as cholesterol exporter, we hypothesized that loss of
ABCA1 efflux function promotes carcinogenesis presumably
via increasing intracellular cholesterol levels. Similarly, we
wanted to explore whether somatic mutations in the ABCA1
gene found in human colon cancers following genomic DNA
sequencing (Sjo¨blom et al., 2006) cause defects in ABCA1 efflux
function and thus may facilitate malignant cell transformation.
RESULTS
ABCA1-Mediated Tumor Inhibition
Cooperation response genes (CRGs) were identified by virtue of
their synergistic regulation by mutant p53175H (mp53) and acti-
vated H-RasV12 (Ras) at the level of polysomal RNA abundance
in young adult mouse colon (YAMC) cells (McMurray et al.,
2008). The list of CRGs includes the gene encoding the choles-
terol exporter ABCA1, which is synergistically downregulated
both at RNA (McMurray et al., 2008) and protein (Figure 1A) levels
in cells expressing mp53 and Ras (mp53/Ras cells), as
compared to cells expressing either mp53 or Ras alone.
Gene perturbation experiments indicate that ABCA1 has
strong antitumor activity. Ectopic ABCA1 reexpression in
mp53/Ras cells to levels approximating those found in the
parental YAMC cells, i.e., ABCA1 reconstitution, (Figure 1B)
caused a marked reduction in the size of tumors forming after
implantation of the genetically modified cells into the flanks ofCelimmunocompromised mice (Figure 1C). ABCA1-associated
tumor inhibition is further indicated by the loss of ectopic
Abca1 expression in the resulting tumors. Abca1 mRNA levels
were found 3-fold lower in tumor tissue than in cells prior to
implantation (Figure S1A), presumably due to rapid selection
from the retrovirally transduced polyclonal cell population ex-
pressing ectopic Abca1 at various levels. Consistent with this
interpretation, ectopic expression of genes not affecting tumor
growth was observed to remain relatively stable following
implantation into mice (example shown in Figures S1B and
S1C). Taken together, these results indicate a causal role for
ABCA1 loss of function in malignant cell transformation. As
ABCA1-reconstituted cells were rapidly excluded from tumors,
analysis of mechanisms underlying ABCA1-mediated tumor inhi-
bition in tumor tissue was not feasible. We observed, however,
that ABCA1-reconstituted mp53/Ras cells showed increased
rates of nonapoptotic cell death/necrosis in vitro, as compared
to unperturbed controls, when cells were cultivated at a low
cell density and in the absence of serum and other survival
factors (Figure 1D). Under similar conditions proliferation rates
remained unaffected (data not shown). This suggests that loss
of ABCA1 expression, as found in mp53/Ras cells contributes
to the relative cell death resistance characteristic of cancer cells.
ABCA1 loss of function in cardiovascular pathogenesis is
associated with diminished cholesterol export activity and thus
increased intracellular cholesterol (Singaraja et al., 2006). A
similar scenario may result from suppression of ABCA1 expres-
sion in malignant cell transformation induced by cooperating
oncogenic mutations. In fact, perturbations of the cholesterol
synthesis pathway mimic the effects of ABCA1 reconstitution.
Several steps downstream of HMG-CoAR, in the cholesterol
biosynthetic pathway, lanosterol cyclase (LC) produces the first
sterol intermediate, and pharmacological inhibition of this
enzyme has been demonstrated to block cholesterol synthesis
(Dollis and Schuber, 1994). As we show here, both a pharmaco-
logical LC inhibitor, and genetic perturbation of LC protein via
small hairpin RNA (shRNA)-mediated knockdown (Figures
S1D–S1F) induce cell death as observed for ABCA1 reconstitu-
tion (Figure 1D). Moreover, tumors arising after implantation of
LC knockdown cells into mice efficiently escape from LC knock-
down (Figure S1G), consistent with a tumor-inhibitory effect of
LC knockdown and presumably due to negative selection.
ABCA1 LowersMitochondrial Cholesterol and Promotes
Cytochrome c Release
Due to its role as a cholesterol exporter, reconstitution of ABCA1
expression in mp53/Ras cells up to levels found in untrans-
formed parental YAMC cells (Figure 1B) is predicted to induce
depletion of cellular cholesterol stores. Increased cholesterol in
cancer cells has been found specifically in mitochondria (Feo
et al., 1973; Feo et al., 1975; Montero et al., 2008). This led us
to measure cholesterol levels in mitochondrial fractions, where
we observed significantly lower levels of cholesterol in samples
from ABCA1-reconstituted mp53/Ras cells as compared to
controls (Figures 2A and S2A). Comparison of cholesterol levels
in total cell membranes, however, indicated no significant overall
differences between ABCA1-reconstituted and control mp53/
Ras cells (data not shown).l Reports 2, 580–590, September 27, 2012 ª2012 The Authors 581
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Figure 1. Reconstitution of ABCA1 Expression Inhibits Tumor
Formation
(A) Western blot showing murine ABCA1 protein expression in YAMC, mp53,
Ras, and mp53/Ras cells.
(B) Western blot showing stable re-expression of ectopic murine ABCA1 in
mp53/Ras cells to levels found in YAMC parental cells. Tubulin served as
loading control for western blots.
(C) Vector control or ABCA1-reconstituted mp53/Ras cells were subcutane-
ously injected in the flanks of nude mice and tumor volumes were measured at
582 Cell Reports 2, 580–590, September 27, 2012 ª2012 The AuthorElevated cholesterol levels as found in the membranes of
cancer cell mitochondria decrease membrane fluidity (Colell
et al., 2003; Montero et al., 2008). This, in turn, inhibits mitochon-
drial permeability transition (MPT) and the associated matrix
swelling and release from mitochondria of cell-death-promoting
molecules such as cytochrome c (Colell et al., 2003; Montero
et al., 2008), presumably supporting cancer cell survival.
Conversely, lowering mitochondrial cholesterol in cancer cells,
as in the case of increased ABCA1 expression, would be pre-
dicted to increase sensitivity to MPT in response to stress. We
thus hypothesized that ABCA1-associated tumor inhibition
may be linked to its ability to lower mitochondrial cholesterol.
Consistent with this idea, mitochondria from ABCA1-reconsti-
tuted mp53/Ras cells (Figure 1B) released more cytochrome c
(Figure 2C) andweremore sensitive tomatrix swelling (Figure 2E)
in response to Ca2+ than mitochondria from controls. Notably,
we also could show that the ABCA1-mediated sensitization of
both cytochrome c release and matrix swelling is dependent
on the associated decrease in mitochondrial cholesterol. This
is demonstrated by the inhibition of ABCA1-induced cytochrome
c release andmatrix swelling, following restoration of cholesterol
in isolated mitochondria to levels found in controls (Figures 2A,
2C, and 2E).
Independent support that lowering mitochondrial cholesterol
is sufficient to enable mitochondrial cytochrome c release in
response to stress comes from experiments targeting the
cholesterol synthesis pathway via knockdown of LC in mp53/
Ras cells (Figure S1F). This perturbation not only induces
a reduction in mitochondrial cholesterol (Figures 2B and S2A),
but also increased mitochondrial sensitivity to calcium-induced
cytochrome c release (Figure 2D) andmatrix swelling (Figure 2F),
to levels similar to those seen in ABCA1-reconstituted cells
(Figures 2A, 2C, and 2E). Moreover, restoration of cholesterol
in mitochondria from LC knockdown cells reversed this sensiti-
zation (Figures 2B, 2D, and 2F). In this context it is relevant to
mention that cell death was not detected in any cells used for
preparation of mitochondria, as these cells were cultured at
higher cell densities than cells used for measuring the impact
of ABCA1 reconstitution and LC knockdown on cell survival.
Our data thus suggest reduction of mitochondrial cholesterol
as a causal factor in ABCA1-mediated matrix swelling and cyto-
chrome c release.
In addition to lowering mitochondrial cholesterol, ABCA1 has
been associated with decreased lipid raft cholesterol (without
detectable alterations in overall levels of plasma membrane
cholesterol) and reduced Akt activity (Landry et al., 2006). A
reduction in Akt-dependent survival signaling thus may alsoindicated times after injection. Values represent average of 16 tumors and
error bars indicate standard deviation at each time point. *p < 0.001, by
Student’s t test.
(D) Cell death of vector control and ABCA1-reconstituted mp53/Ras cells
(ABCA1). Cell death was measured by trypan blue exclusion (left panel), with
no indication for DNA fragmentation/apoptosis, as measured by TUNEL
staining (right panel). Values represent the average of three independent
experiments. Error bars indicate standard deviation. *p < 0.01 versus vector
control, by Student’s t test.
See also Figure S1.
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Figure 2. ABCA1 Reconstitution and
Knockdown of LC Decrease Mitochondrial
Cholesterol and Increase Sensitivity to
Calcium-Induced Cytochrome c Release
and Matrix Swelling
(A and B) Cholesterol in mitochondria from
vector control, ABCA1-reconstituted (ABCA1),
and lanosterol cyclase knockdown (LC kd) mp53/
Ras cells and following cholesterol restoration
(ABCA1+Chol and LC kd+Chol). Cholesterol levels
determined by Amplex Red cholesterol assay and
normalized to total mitochondrial protein. Indi-
cated values represent average from three inde-
pendent experiments and (B) two independent
LC shRNA constructs. Error bars indicate SD,
**p < 0.01 versus vector by Student’s t test.
(C and D) Calcium-induced release of cytochrome
c (Cyt C) frommitochondria of cells indicated in (A)
and (B). Cyt C was measured by western blot, with
cytochrome oxidase I (COX1) serving as loading
control. Blots shown are representative of three
independent experiments.
(E and F) Calcium-induced swelling of mitochon-
dria from cell lines indicated in (A) and (B). Mito-
chondrial swelling was assessed by measuring
changes in absorbance at 540 nm. Error bars
indicate standard deviation, *p < 0.001 versus
vector by Student’s t test.
See also Figure S2.contribute to the anticancer activity of ABCA1. We found,
however, no evidence for decreased AKT activity in response
to ABCA1 reconstitution in mp53/Ras cells, as indicated by unal-
tered phosphorylation at AKT residues Ser473 and Thr308 (data
not shown). This may be due to the presence of activated Ras in
the mp53/Ras cells, a potent activator of AKT (Repasky et al.,
2004). AKT inhibition thus appears unlikely to contribute to
ABCA1-associated tumor inhibition in mp53/Ras cells. More-
over, in our system we were unable to confirm reports linking
increased cholesterol to elevated endoplasmic reticulum stress
and the associated unfolded protein response (Tabas, 2010)
(data not shown).
Our data described above indicate that mitochondrial
cholesterol in cancerous cells is controlled effectively by both
cholesterol biosynthesis and the cholesterol exporter ABCA1.
Consistent with this idea, elevated mitochondrial cholesterol in
mp53/Ras cells is accompanied not only by reduced ABCA1
expression (Figure 1A), but also by increased cholesterol
synthesis rates, as compared to YAMC, Ras, or mp53 cells (Fig-Cell Reports 2, 580–590, Seure S2B). Correspondingly, levels of mito-
chondrial cholesterol in mp53/Ras cells
are uniquely higher than in YAMC, Ras,
or mp53 cells (Figures S2C and S2D). As
one might predict in such a context,
decreasing ABCA1 expression in cells in
which cholesterol synthesis is not fully
activated, i.e., reduction of ABCA1 levels
in Ras and mp53 cells to levels found in
mp53/Ras cells (Figure S2E), did not
increase mitochondrial cholesterol (Fig-ure S2D), presumably because of insufficient supply. Moreover,
mitochondrial cholesterol is also not increased by an additional
reduction of ABCA1 expression in malignant mp53/Ras cells
(Figure S2D), suggesting saturation of mitochondrial cholesterol
in these cells. Notably, in either context tumor formation
capacity was not affected (Figures S2F and S2G), presumably
because mitochondrial cholesterol levels remained unaltered.
Taken together, it thus seems reasonable to suggest that
ABCA1 functions to restrict tumor growth via maintaining mito-
chondrial cholesterol at levels incompatible with the cancer
phenotype, particularly in the presence of elevated rates of
cholesterol synthesis that would otherwise drive up mitochon-
drial cholesterol.
Based on our data summarized above, we hypothesized that
elevatedmitochondrial cholesterol can promote increased death
resistance in cancer cells and thusmalignant cell transformation.
Such a view is supported by work of others showing that RNA
interference knockdown of squalene synthase, the enzyme cata-
lyzing the first committed step of cholesterol synthesis, leads toptember 27, 2012 ª2012 The Authors 583
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Figure 3. Suppression of CypD or Ant1 Restores Death Resistance
of ABCA1-Reconstituted mp53/Ras Cells In Vitro and Rescues
Tumor Growth In Vivo
(A and B) Cell death of the indicated derivatives of mp53/Ras cells: vector
control (Vector/Vector), ABCA1-reconstituted (ABCA1/Vector), ABCA1-re-
constituted plus cyclophilin D knockdown (ABCA1/CypD-sh3 and -sh5) or
Adenine Nucleotide Translocator 1 knockdown (ABCA1/Ant1-sh3 and -sh4),
cyclophilin D knockdown (Vector/CypD-sh3 or -sh5), and Adenine Nucleotide
Translocator 1 knockdown (Vector/Ant1-sh3 or -sh4). Cell death was
measured by trypan blue exclusion. Values represent the average of three
584 Cell Reports 2, 580–590, September 27, 2012 ª2012 The Authordecreased cell proliferation and survival of prostate cancer cells
in vitro (Bresselmans et al., 2007), and that shRNA-mediated
knockdown of the steroidogenic acute regulatory protein
(StAR), a mitochondrial protein that transports cholesterol into
mitochondria, sensitized hepatocellular carcinoma cells to
chemotherapeutic agents in vitro (Montero et al., 2008). Never-
theless, direct demonstration of a causal role of metabolites,
such as cholesterol, in intact cells cannot be achieved by genetic
manipulation. We thus further examined the validity of our
hypothesis by testing several independent predictions in a variety
of biological contexts.
ABCA1 Promotes Mitochondria-Mediated Cell Death
in Cancer Cells
ABCA1 promotes reduction in mitochondrial cholesterol, MPT-
associated cytochrome c release, and non-apoptotic/necrotic
cell death in response to cell stress, suggesting that ABCA1-
mediated cell death depends on cholesterol for modulation of
mitochondrial function. We tested this prediction in two steps,
first by examining whether ABCA1-induced cell death requires
MPT pore components and second by testing whether reduction
of mitochondrial cholesterol levels by independent means can
mimic the effects of ABCA1 reexpression. Mitochondria-depen-
dent cell death occurs following MPT, during which mitochon-
drial proteins form membrane pores that enable the release of
molecules such as cytochrome c, which can initiate both
apoptotic and nonapoptotic cell death. (Kroemer et al., 2007;
Nakagawa et al., 2005). Cyclophilin D (CypD) and the adenine
nucleotide translocator (Ant1) are two mitochondrial proteins
that play key roles in initiating MPT (Baines et al., 2005; Lee
et al., 2009; Nakagawa et al., 2005). To test whether CypD
or Ant1 are required for the increased death sensitivity of
ABCA1-positive mp53/Ras cells and ABCA1 anticancer activity,
we lowered expression of CypD or Ant1 via shRNA-mediated
knockdown. We found that both CypD and Ant1 are essential
for ABCA1-mediated death sensitization and tumor inhibition
(Figure 3), suggesting that the antitumor activity of ABCA1
requires mitochondrial function. In addition, reduction of mito-
chondrial cholesterol following knockdown of LC in mp53/Ras
cells not only induces cytochrome c release (Figure 2), but also
facilitates cell death in a CypD- and Ant1-dependent manner
(Figure S3) indistinguishable from ABCA1-positive cells. Taken
together, these data support the idea that ABCA1-induced
reduction of mitochondrial cholesterol sensitizes cancer cells
to stimuli or stresses promoting cell death.independent experiments, and error bars indicate SD. *p < 0.01 versus all
other cell lines, by Student’s t test.
(C and D) Box plots indicating the volumes of tumors 4 weeks after subcuta-
neous implantation of the mp53/Ras cell derivatives indicated in (A, B). Each
box shows the range from the first to third quartile of the tumor volumes. The
line in the box indicates the median tumor volume. The bars represent the
largest and smallest tumors. *p < 0.01 versus all other cell lines, by Student’s
t test.
(E and F) Western blots showing expression of ABCA1. Tubulin serves as
a loading control.
(G and H) Expression of CypD and Ant1 was measured by real-time quanti-
tative PCR. Error bars indicate SD.
See also Figure S3.
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Figure 4. Loss of ABCA1 Efflux Function
CorrelateswithReducedTumorSuppression
(A and B) Box plots indicating the volumes of
tumors 5 weeks after subcutaneous implantation
of the indicated derivatives of human colon cancer
cell lines: (A) HT-29 and (B) DLD-1 expressing wild-
type human ABCA1 (hABCA1 WT) or the indicated
ABCA1 mutants. Each box shows the range from
the first to third quartile of the tumor volumes. The
line in the box indicates the median tumor volume.
The bars represent the largest and smallest
tumors. *p < 0.01 versus WT hABCA1 expressing
cell line, by Student’s t test.
(C and D) Cholesterol efflux capacities of hABCA1
mutants expressed in (A) HT-29 and (B) DLD-1
cells relative to hABCA1 wild-type. Values indi-
cate percentage of wild-type efflux and rep-
resent the average of three independent
experiments. Error bars indicate SD. *p < 0.01
versus WT hABCA1 expressing cell line, by
Student’s t test. Images below each graph are
western blots showing representative protein
expression of WT and mutant hABCA1 in cell lines
used in (A)–(D).
See also Figure S4.Cholesterol Efflux Function Linked to ABCA1 Antitumor
Activity
Further evidence substantiating a causal link between ABCA1-
mediated tumor inhibition and mitochondrial cholesterol deple-
tion comes from testing the dependence of ABCA1 anticancer
activity on its efflux capacity. To this end, we utilized two
missense mutations of human ABCA1 proteins (Q597R and
C1477R) linked to TD and familial hypoalphalipoproteinemia
(FHA), which were previously characterized to have diminished
cholesterol efflux activity (Singaraja et al., 2006). Functionality
of these ABCA1mutants in terms of tumor inhibition and choles-
terol efflux was tested in human cancer cells lacking endoge-
nous ABCA1 expression, as preliminary experiments revealed
that human ABCA1 is inactive in murine cells, indicating
a cross-species incompatibility (data not shown). We thus first
confirmed that ectopically expressed wild-type human ABCA1
inhibited tumor growth of HT-29 and DLD-1 human colon cancerCell Reports 2, 580–590, Secells when implanted subcutaneously
into immunocompromised mice and
increased cholesterol efflux capacity in
both cell types (Figure 4). In contrast,
both TD/FHA mutants, although ex-
pressed to similar levels as wild-type
ABCA1, did not decrease tumor forma-
tion, and as expected were deficient for
cholesterol efflux (Figure 4), thus support-
ing a causal link between ABCA1’s anti-
tumor activity and its efflux capacity.
Notably, somatic mutations in the
ABCA1 gene have been discovered
following genomic sequencing of human
colon cancer samples. In addition to the
well-known cancer genes (i.e., p53, Apc,and Ras), ABCA1 placed in the top group of genes mutated in
human colon cancers at low frequency, with four separately
occurring single base pair substitutions identified (Sjo¨blom
et al., 2006). Given the correlation between tumor inhibition and
efflux activity of ABCA1 described above, we sought to test
whether theABCA1coloncancermutations affect effluxandanti-
tumor activity similar to theTD/FHAmutants.We thus engineered
each of these four colon-cancer-associated mutations individu-
ally into a human ABCA1 cDNA to test their effects on ABCA1
functionality. Two of the mutants (A1407T and A2109T) demon-
strated a marked reduction in both cholesterol efflux and anti-
tumor activity, while the other two mutants (E210D and D917Y)
showed activity indistinguishable from the wild-type (wt)
ABCA1 cDNA in both assays and in both human cancer cell lines
used (Figure 4). Our data thus identify ABCA1 human colon
cancer mutations A1407T and A2109T as loss-of-function muta-
tions disabling both cholesterol efflux and antitumor activity.ptember 27, 2012 ª2012 The Authors 585
Additional evidence to support the conclusion that efflux-
deficient ABCA1 mutants lose antitumor activity is provided
by ABCA1 expression analysis in tissue samples pre- and
postimplantation into mice. While expression of wt ABCA1 is
strongly reduced following transplantation (see also Figure S1A
for murine Abca1), expression of loss-of-function ABCA1
mutants A1407T and A2109T remains relatively unchanged,
presumably because their antitumor activity is strongly dimin-
ished (Figure S4).
In summary, our data reveal a close correlation between
cholesterol efflux capacity, reduction of mitochondrial choles-
terol in presence of elevated cholesterol synthesis rates, and
antitumor activity of ABCA1. We also demonstrate a loss-of-
function phenotype for somatic mutations identified in human
colon cancer and thus suggest a role of ABCA1 as a tumor
suppressor, albeit specifically in the context of increased choles-
terol synthesis rates competent to raise levels of mitochondrial
cholesterol.
DISCUSSION
Here, we demonstrate an anticancer function of the cholesterol
exporter ABCA1 in human cancer cells. Our data link malignant
cell transformation to defective cholesterol efflux, either
following suppression of ABCA1 gene expression in response
to cooperating oncogenic mutations or loss-of-function muta-
tion. ABCA1 deficiency allows for elevatedmitochondrial choles-
terol and ultimately supports cancer cell survival. We suggest
that this involves increased retention of cell death-promoting
molecules in mitochondria, presumably due to decreased
membrane fluidity and inhibition of MPT (Colell et al., 2003;
Montero et al., 2008). Conversely, ABCA1 antitumor activity
requires efflux function and appears to be mediated by reduced
mitochondrial cholesterol combined with an increased potential
for release of cell death promoting molecules, such as cyto-
chrome c, from mitochondria.
ABCA1 loss-of-functionmutations play a causal role in TD and
FHA, cardiovascular conditions characterized by abnormally low
levels of plasma HDL cholesterol (HDL-C) (Rust et al., 1999).
Missense mutations identified in the ABCA1 gene of TD/FHA
patients reduce efflux function, leading to a diminished ability
of ABCA1 to export excess intracellular cholesterol to apolipo-
protein A1, forming HDL-C particles (Singaraja et al., 2006).
While TD/FHA has not been linked to cancer, possibly due to
the relatively low incidence of TD/FHA, low serum HDL levels,
a characteristic feature of TD/FHA, correlate with higher inci-
dence of multiple cancers (Liu et al., 2011; McGrowder et al.,
2011; Van Hemelrijck et al., 2011). Our finding that multiple inde-
pendent ABCA1 missense mutations found in TD/FHA patients
and human colon cancers show loss of both cholesterol export
function and antitumor activity, supports an anticancer function
of ABCA1 in human malignancy. In addition our data strongly
argue in favor of a causal link between export and anticancer
functions.
Genome-scale DNA sequencing of human cancer samples
has revealed tumor-associated genetic alterations, thus identi-
fying numerous candidate oncogenes or tumor suppressor
genes (Beroukhim et al., 2010; Cancer Genome Atlas Research586 Cell Reports 2, 580–590, September 27, 2012 ª2012 The AuthorNetwork, 2008; Ding et al., 2008; Sjo¨blom et al., 2006). Specifi-
cally, sequencing DNA from human colon cancer specimen
identified, among others, four independently occurring somatic
mutations in the ABCA1 gene, albeit with lower frequency than
the well-known oncogenic mutations in genes such as Apc,
p53, and Ras (Sjo¨blom et al., 2006). Here we demonstrate that
two of four mutations identified in colon cancer samples are
loss-of-function mutations. The two other ABCA1 mutations, in
contrast, had no significant effects on ABCA1-mediated efflux
or tumor inhibition, and thus may represent functionally neutral
passenger mutations serendipitously coselected with other
cancer-relevant driver mutations (Forrest and Cavet, 2007;
Getz et al., 2007; Parmigiani et al., 2007; Rubin and Green,
2007). Alternatively, these mutations may exhibit a subtle and
rather context-dependent loss-of-function phenotype, e.g.,
dependence on intermolecular interactions, that remains unde-
tected in our experimental models.
Diminished cholesterol efflux can be presumed a likely conse-
quence of somatic ABCA1 loss-of-function mutations in human
colon cancers, although the mutations were found to be hetero-
zygous (Sjo¨blom et al., 2006). While TD/FHA patients exhibiting
almost complete absence of plasma HDL-C are typically homo-
zygous for ABCA1 loss-of-function mutations, heterozygosity of
ABCA1 is sufficient to produce intermediate HDL-C deficiencies
(Singaraja et al., 2006). This suggests haploinsufficiency for
ABCA1 function, thus rendering cholesterol export particularly
vulnerable not only to gene mutation but also to partial suppres-
sion of ABCA1 gene expression, particularly in scenarios where
this will lead to increased mitochondrial cholesterol. In fact, inhi-
bition of ABCA1 expression has been observed in human colon,
breast, lymphoblastic, and liver cancer specimen (Basso et al.,
2005; Ki et al., 2007; Moustafa et al., 2004; Schimanski et al.,
2009), indicating decreased ABCA1 efflux activity in a variety
of human cancers.
In addition to loss of cholesterol export activity, ABCA1muta-
tions linked to TD/FHA, including those utilized in the current
study, also show deficiency in phosholipid efflux (Singaraja
et al., 2006). As a key component of HDL particles, phospho-
lipids play an important role in the removal of cellular cholesterol
(Attie, 2007) and thus diminished phospholipid efflux may exac-
erbate defects in cholesterol efflux. Although we cannot exclude
the possibility that ABCA1 loss-of-function effects are in part
mediated by metabolites such as phospholipids, extensive
experimentation described above indicates that lowering
cholesterol synthesis closely mimics the effects of ABCA1
suppression or loss of function, thus suggesting cholesterol as
a key driver of the observed effects.
Cholesterol lowering drugs, such as statins, in use for their
benefits in cardiovascular disease have been evaluated for their
efficacy in prevention and treatment of cancer. A variety of retro-
spective studies have revealed association between long-term
statin use and lower cancer incidence (Cauley et al., 2003;
Farwell et al., 2008; Karp et al., 2008; Khurana et al., 2007;
Poynter et al., 2005; Shannon et al., 2005), as well as improved
outcome (Gutt et al., 2010; Kawata et al., 2001; Nowakowski
et al., 2010; Siddiqui et al., 2009). In addition, when combined
with chemotherapy, statins significantly augment efficacy of
therapy in patients with acute myelogenous leukemia (Kornblaus
et al., 2007), while little to no anticancer effects of statins have
been observed when used in patients as single agents (Holstein
et al., 2006; Knox et al., 2005; Thibault et al., 1996). Therapeutic
efficacy of statins in combination with chemotherapy may be
due to the capability of statins to sensitize cancer cells to
chemotherapy-induced cell death (Kornblau et al., 2007). This
chemosensitization is consistent with the antitumor mechanism
of lowering cholesterol proposed here and by others (Montero
et al., 2008), where decreased cholesterol in mitochondria leads
to increased sensitivity to stimuli inducing cell death, presumably
by facilitating MPT.
The in vivo genetic evidence provided here reveals anticancer
activity of the cholesterol exporter ABCA1, which can be
disabled by ABCA1 loss-of-function mutations or suppression
of ABCA1 gene expression in response to cooperating onco-
genic mutations. Moreover, we suggest that loss of ABCA1-
mediated efflux is a key step in allowing the accumulation of
mitochondrial cholesterol levels that support cancer survival.
Taken together, our data thus support a causal role for elevated
mitochondrial cholesterol in cancer cells and provide a mecha-
nistic rationale for cholesterol targeting as a potentially fruitful
approach to augment cancer intervention and/or prevention
strategies.
EXPERIMENTAL PROCEDURES
Cells
Young adult mouse colon (YAMC) cells (Whitehead et al., 1993), and YAMC
cells expressing p53175H (mp53), HRasV12 (Ras), and both p53175H and
HRasV12 (mp53/Ras) cells were maintained as previously described (McMur-
ray et al., 2008; Xia and Land, 2007). DLD-1 human colon cancer cells were
provided byDr. J. Filmus andHT-29 human colon cancer cells were purchased
from ATCC. Both human cell lines were cultured at 37C in DMEM media
(Invitrogen) supplemented with 10% FBS (Hyclone) and 2.5 mg/ml genamycin
(Invitrogen). See Extended Experimental Procedures for derivation of geneti-
cally perturbed cells.
Xenograft Assay
Tumor formationwas assayed as previously described (McMurray et al., 2008).
See Extended Experimental Procedures for detailed description.
Cell Death Assays
Prior to cell death assay, mp53/Ras cells were grown at 39C for at least 48 hr.
To assess resistance to cell death, mp53/Ras cells were seeded at low density
(2,265 cells/cm2) in standard RPMI growth media. Sixteen hours later, cells
were washed with PBS and then given RPMI media devoid of serum and
ITS. Media given to ABCA1-reconstituted and matched vector control
mp53/Ras cells was also supplemented with 20 mg/ml apolipoprotein A1
(Meridian Life Science) to lower intracellular cholesterol by inducing choles-
terol efflux. These cells were given a second dose of 20 mg/ml apolipoprotein
48 hr later. Cell death was measured 72 hr after initial starvation by trypan blue
exclusion assay as described in product manual (Invitrogen), or fixed in 4%
paraformaldehyde and TUNEL stained (Roche). The amount of TUNEL-posi-
tive cells was quantified via fluorescence-activated cell sorting analysis.
Intracellular Cholesterol Measurements
Prior to measuring intracellular cholesterol, cells were grown at 39C for at
least 48 hr followed by growth in RPMI media, devoid of serum and ITS,
for 72 hr. Media given to ABCA1-reconstituted, ABCA1-knockdown, and
matched vector control cells during this 72 hr time period was also supple-
mented with 20 mg/ml apolipoprotein A1 to induce cholesterol efflux. A second
dose of 20 mg/ml apolipoprotein A1 was given after 48 hr. Intracellular choles-
terol levels were determined using the Amplex Red Cholesterol Assay KitCel(Invitrogen) or thin layer chromatography. See Extended Experimental Proce-
dures for more detailed description of cholesterol measurements.
Mitochondrial Cholesterol Loading, Matrix Swelling,
and Cytochrome c Release Assays
Cholesterol levels were restored in cholesterol-depleted mitochondria of
ABCA1-reconstituted and lanosterol cyclase-knockdown mp53/Ras cells as
described previously (Montero et al., 2008). Sensitivity to calcium-induced
mitochondrial matrix swelling and cytochrome c release was then determined
as previously described (Montero et al., 2008).
Cholesterol Efflux Assay
Cholesterol efflux was measured as previously described (Singaraja et al.,
2006). Briefly, cells were given 1 mCi/ml [H3]cholesterol (Perkin-Elmer) for
16 hr, followed by washing with PBS containing 0.2% fatty acid free BSA
(Sigma). Cells were then incubated for 24 hr in serum free DMEM containing
0.2% fatty acid free BSA and 20 mg/ml Apolipoprotein A1. Following incuba-
tion, media containing effluxed cholesterol was collected and centrifuged at
10,000 3 g for 5 min to remove debris. Radioactivity was quantified by liquid
scintillation and normalized to total protein. Efflux rate was calculated as
a percentage of efflux by wild-type ABCA1 and indicated values represent
the average of three independent experiments.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2012.08.011.
Licensing Information
This is an open-access article distributed under the terms of the Creative
Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported
License (CC-BY-NC-ND; http://creativecommons.org/licenses/by-nc-nd/3.0/
legalcode).
ACKNOWLEDGMENTS
We would like to thank Dr. D. Brdiczka for critical advice and discussion,
Dr. H. McMurray for helpful suggestions, and Drs. A.R. Tall, M.R. Hayden,
and J. Filmus for reagents. This work was supported by NIH Grants
CA90663, CA120317, and CA138249.
Received: August 1, 2011
Revised: April 20, 2012
Accepted: August 15, 2012
Published online: September 13, 2012
REFERENCES
Attie, A.D. (2007). ABCA1: at the nexus of cholesterol, HDL and atheroscle-
rosis. Trends Biochem. Sci. 32, 172–179.
Baines, C.P., Kaiser, R.A., Purcell, N.H., Blair, N.S., Osinska, H., Hambleton,
M.A., Brunskill, E.W., Sayen, M.R., Gottlieb, R.A., Dorn, G.W., et al. (2005).
Loss of cyclophilin D reveals a critical role for mitochondrial permeability tran-
sition in cell death. Nature 434, 658–662.
Basso, K., Margolin, A.A., Stolovitzky, G., Klein, U., Dalla-Favera, R., and
Califano, A. (2005). Reverse engineering of regulatory networks in human B
cells. Nat. Genet. 37, 382–390.
Benn, M., Tybjærg-Hansen, A., Stender, S., Frikke-Schmidt, R., and Nordest-
gaard, B.G. (2011). Low-density lipoprotein cholesterol and the risk of cancer:
a mendelian randomization study. J. Natl. Cancer Inst. 103, 508–519.
Beroukhim, R., Mermel, C.H., Porter, D., Wei, G., Raychaudhuri, S., Donovan,
J., Barretina, J., Boehm, J.S., Dobson, J., Urashima, M., et al. (2010). The land-
scape of somatic copy-number alteration across human cancers. Nature 463,
899–905.l Reports 2, 580–590, September 27, 2012 ª2012 The Authors 587
Bresselmans, K., Timmermans, L., Van de Sande, T., Veldhoven, P., Guan, G.,
Shechter, I., Claessens, F., Verhoeven, G., and Swinnen, J. (2007). Squalene
Synthase: a determinant of raft-associated cholesterol and modulator of
cancer cell proliferation. J. Biol. Chem. 282, 18777–18785.
Cancer Genome Atlas Research Network. (2008). Comprehensive genomic
characterization defines human glioblastoma genes and core pathways.
Nature 455, 1061–1068.
Caruso, M.G., Notarnicola, M., Santillo, M., Cavallini, A., and Di Leo, A. (1999).
Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in
human colorectal cancer not expressing low density lipoprotein receptor. Anti-
cancer Res. 19 (1A), 451–454.
Caruso, M.G., Notarnicola, M., Cavallini, A., and Di Leo, A. (2002). 3-Hydroxy-
3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein
receptor expression in diffuse-type and intestinal-type human gastric cancer.
J. Gastroenterol. 37, 504–508.
Cauley, J.A., Zmuda, J.M., Lui, L.Y., Hillier, T.A., Ness, R.B., Stone, K.L., Cum-
mings, S.R., and Bauer, D.C. (2003). Lipid-lowering drug use and breast
cancer in older women: a prospective study. J. Womens Health (Larchmt)
12, 749–756.
Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten,
R.E., Wei, R., Fleming, M.D., Schreiber, S.L., and Cantley, L.C. (2008). The M2
splice isoform of pyruvate kinase is important for cancer metabolism and
tumour growth. Nature 452, 230–233.
Chuu, C.P., and Lin, H.P. (2010). Antiproliferative effect of LXR agonists
T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines.
Anticancer Res. 30, 3643–3648.
Chuu, C.P., Hiipakka, R.A., Kokontis, J.M., Fukuchi, J., Chen, R.Y., and Liao,
S. (2006). Inhibition of tumor growth and progression of LNCaP prostate
cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer
Res. 66, 6482–6486.
Colell, A., Garcı´a-Ruiz, C., Lluis, J.M., Coll, O., Mari, M., and Ferna´ndez-
Checa, J.C. (2003). Cholesterol impairs the adenine nucleotide translocator-
mediated mitochondrial permeability transition through altered membrane
fluidity. J. Biol. Chem. 278, 33928–33935.
Demierre, M.F., Higgins, P.D., Gruber, S.B., Hawk, E., and Lippman, S.M.
(2005). Statins and cancer prevention. Nat. Rev. Cancer 5, 930–942.
Dessı´, S., Batetta, B., Anchisi, C., Pani, P., Costelli, P., Tessitore, L., and
Baccino, F.M. (1992). Cholesterol metabolism during the growth of a rat
ascites hepatoma (Yoshida AH-130). Br. J. Cancer 66, 787–793.
Dessı`, S., Batetta, B., Pulisci, D., Spano, O., Anchisi, C., Tessitore, L., Costelli,
P., Baccino, F.M., Aroasio, E., and Pani, P. (1994). Cholesterol content in tumor
tissues is inversely associated with high-density lipoprotein cholesterol in
serum in patients with gastrointestinal cancer. Cancer 73, 253–258.
Ding, L., Getz, G., Wheeler, D.A., Mardis, E.R., McLellan, M.D., Cibulskis, K.,
Sougnez, C., Greulich, H., Muzny, D.M., Morgan, M.B., et al. (2008). Somatic
mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–
1075.
Dollis, D., and Schuber, F. (1994). Effects of a 2,3-oxidosqualene-lanosterol
cyclase inhibitor 2,3:22,23-dioxidosqualene and 24,25-epoxycholesterol on
the regulation of cholesterol biosynthesis in human hepatoma cell line
HepG2. Biochem. Pharmacol. 48, 49–57.
Fantin, V.R., St-Pierre, J., and Leder, P. (2006). Attenuation of LDH-A expres-
sion uncovers a link between glycolysis, mitochondrial physiology, and tumor
maintenance. Cancer Cell 9, 425–434.
Farwell, W.R., Scranton, R.E., Lawler, E.V., Lew, R.A., Brophy, M.T., Fiore,
L.D., and Gaziano, J.M. (2008). The association between statins and cancer
incidence in a veterans population. J. Natl. Cancer Inst. 100, 134–139.
Feo, F., Canuto, R.A., Bertone, G., Garcea, R., and Pani, P. (1973). Cholesterol
and phospholipid composition of mitochondria and microsomes isolated from
morris hepatoma 5123 and rat liver. FEBS Lett. 33, 229–232.
Feo, F., Canuto, R.A., Garcea, R., and Gabriel, L. (1975). Effect of cholesterol
content on some physical and functional properties of mitochondria isolated588 Cell Reports 2, 580–590, September 27, 2012 ª2012 The Authorfrom adult rat liver, fetal liver, cholesterol-enriched liver and hepatomas
AH-130, 3924A and 5123. Biochim. Biophys. Acta 413, 116–134.
Forrest, W.F., and Cavet, G. (2007). Comment on ‘‘The consensus coding
sequences of human breast and colorectal cancers’’. Science 317, 1500,
author reply 1500.17872427.
Gao, J., Jia,W.D., Li, J.S.,Wang,W., Xu, G.L., Ma, J.L., Ge, Y.S., Yu, J.H., Ren,
W.H., Liu, W.B., and Zhang, C.H. (2010). Combined inhibitory effects of cele-
coxib and fluvastatin on the growth of human hepatocellular carcinoma xeno-
grafts in nude mice. J. Int. Med. Res. 38, 1413–1427.
Getz, G., Ho¨fling, H., Mesirov, J.P., Golub, T.R., Meyerson, M., Tibshirani, R.,
and Lander, E.S. (2007). Comment on ‘‘The consensus coding sequences of
human breast and colorectal cancers’’. Science 317, 1500.
Graziani, S.R., Igreja, F.A., Hegg, R., Meneghetti, C., Brandizzi, L.I., Barboza,
R., Amaˆncio, R.F., Pinotti, J.A., andMaranha˜o, R.C. (2002). Uptake of a choles-
terol-rich emulsion by breast cancer. Gynecol. Oncol. 85, 493–497.
Gregg, R.G., Davidson, M., and Wilce, P.A. (1986). Cholesterol synthesis
and HMG CoA reductase activity during hepatocarcinogenesis in rats. Int.
J. Biochem. 18, 389–393.
Gutt, R., Tonlaar, N., Kunnavakkam, R., Karrison, T., Weichselbaum, R.R., and
Liauw, S.L. (2010). Statin use and risk of prostate cancer recurrence in men
treated with radiation therapy. J. Clin. Oncol. 28, 2653–2659.
Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks,
M.W., andWeinberg, R.A. (1999). Creation of human tumour cells with defined
genetic elements. Nature 400, 464–468.
Hentosh, P., Yuh, S.H., Elson, C.E., and Peffley, D.M. (2001). Sterol-indepen-
dent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor
cells. Mol. Carcinog. 32, 154–166.
Holstein, S.A., Knapp, H.R., Clamon, G.H., Murry, D.J., and Hohl, R.J. (2006).
Pharmacodynamic effects of high dose lovastatin in subjects with advanced
malignancies. Cancer Chemother. Pharmacol. 57, 155–164.
Huang, E.H., Johnson, L.A., Eaton, K., Hynes, M.J., Carpentino, J.E., and
Higgins, P.D. (2010). Atorvastatin induces apoptosis in vitro and slows growth
of tumor xenografts but not polyp formation in MIN mice. Dig. Dis. Sci. 55,
3086–3094.
Jacobs, D., Blackburn, H., Higgins, M., Reed, D., Iso, H., McMillan, G., Neaton,
J., Nelson, J., Potter, J., Rifkind, B., et al. (1992). Report of the conference on
low blood cholesterol: mortality associations. Circulation 86, 1046–1060.
Karp, I., Behlouli, H., Lelorier, J., and Pilote, L. (2008). Statins and cancer risk.
Am. J. Med. 121, 302–309.
Kawata, S., Yamasaki, E., Nagase, T., Inui, Y., Ito, N., Matsuda, Y., Inada, M.,
Tamura, S., Noda, S., Imai, Y., and Matsuzawa, Y. (2001). Effect of pravastatin
on survival in patients with advanced hepatocellular carcinoma. A randomized
controlled trial. Br. J. Cancer 84, 886–891.
Khurana, V., Bejjanki, H.R., Caldito, G., and Owens, M.W. (2007). Statins
reduce the risk of lung cancer in humans: a large case-control study of US
veterans. Chest 131, 1282–1288.
Ki, D.H., Jeung, H.C., Park, C.H., Kang, S.H., Lee, G.Y., Lee, W.S., Kim, N.K.,
Chung, H.C., and Rha, S.Y. (2007). Whole genome analysis for liver metastasis
gene signatures in colorectal cancer. Int. J. Cancer 121, 2005–2012.
Knox, J.J., Siu, L.L., Chen, E., Dimitroulakos, J., Kamel-Reid, S., Moore, M.J.,
Chin, S., Irish, J., LaFramboise, S., and Oza, A.M. (2005). A Phase I trial of pro-
longed administration of lovastatin in patients with recurrent or metastatic
squamous cell carcinoma of the head and neck or of the cervix. Eur. J. Cancer
41, 523–530.
Kochuparambil, S.T., Al-Husein, B., Goc, A., Soliman, S., and Somanath, P.R.
(2011). Anticancer efficacy of simvastatin on prostate cancer cells and tumor
xenografts is associated with inhibition of Akt and reduced prostate-specific
antigen expression. J. Pharmacol. Exp. Ther. 336, 496–505.
Kolanjiappan, K., Ramachandran, C.R., and Manoharan, S. (2003). Biochem-
ical changes in tumor tissues of oral cancer patients. Clin. Biochem. 36, 61–65.
Kornblau, S.M., Banker, D.E., Stirewalt, D., Shen, D., Lemker, E., Verstovsek,
S., Estrov, Z., Faderl, S., Cortes, J., Beran, M., et al. (2007). Blockade of
adaptive defensive changes in cholesterol uptake and synthesis in AML bys
the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Blood 109, 2999–3006.
Kroemer, G., Galluzzi, L., and Brenner, C. (2007). Mitochondrial membrane
permeabilization in cell death. Physiol. Rev. 87, 99–163.
Land, H., Parada, L.F., and Weinberg, R.A. (1983). Tumorigenic conversion of
primary embryo fibroblasts requires at least two cooperating oncogenes.
Nature 304, 596–602.
Landry, Y.D., Denis, M., Nandi, S., Bell, S., Vaughan, A.M., and Zha, X. (2006).
ATP-binding cassette transporter A1 expression disrupts raft membrane
microdomains through its ATPase-related functions. J. Biol. Chem. 281,
36091–36101.
Lee, J., Schriner, S.E., andWallace, D.C. (2009). Adenine nucleotide transloca-
tor 1 deficiency increases resistance of mouse brain and neurons to excito-
toxic insults. Biochim. Biophys. Acta 1787, 364–370.
Liu, Y.L., Qian, H.X., Qin, L., Zhou, X.J., and Zhang, B. (2011). Serum LDL-C
and LDL-C/HDL-C ratio are positively correlated to lymph node stages in
males with colorectal cancer. Hepatogastroenterology 58, 383–387.
Lloyd, A.C., Obermu¨ller, F., Staddon, S., Barth, C.F., McMahon, M., and
Land, H. (1997). Cooperating oncogenes converge to regulate cyclin/cdk
complexes. Genes Dev. 11, 663–677.
Luo, J., Emanuele, M.J., Li, D., Creighton, C.J., Schlabach, M.R., Westbrook,
T.F., Wong, K.K., and Elledge, S.J. (2009). A genome-wide RNAi screen iden-
tifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137,
835–848.
McGrowder, D., Riley, C., Morrison, E.Y., and Gordon, L. (2011). The role of
high-density lipoproteins in reducing the risk of vascular diseases, neuroge-
nerative disorders, and cancer. Cholesterol 2011, 496925.
McMurray, H.R., Sampson, E.R., Compitello, G., Kinsey, C., Newman, L.,
Smith, B., Chen, S.R., Klebanov, L., Salzman, P., Yakovlev, A., and Land, H.
(2008). Synergistic response to oncogenic mutations defines gene class
critical to cancer phenotype. Nature 453, 1112–1116.
Montero, J., Morales, A., Llacuna, L., Lluis, J.M., Terrones, O., Basan˜ez, G.,
Antonsson, B., Prieto, J., Garcı´a-Ruiz, C., Colell, A., and Ferna´ndez-Checa,
J.C. (2008). Mitochondrial cholesterol contributes to chemotherapy resistance
in hepatocellular carcinoma. Cancer Res. 68, 5246–5256.
Moustafa, M.A., Ogino, D., Nishimura, M., Ueda, N., Naito, S., Furukawa, M.,
Uchida, T., Ikai, I., Sawada, H., and Fukumoto, M. (2004). Comparative
analysis of ATP-binding cassette (ABC) transporter gene expression levels in
peripheral blood leukocytes and in liver with hepatocellular carcinoma. Cancer
Sci. 95, 530–536.
Nakagawa, T., Shimizu, S., Watanabe, T., Yamaguchi, O., Otsu, K., Yamagata,
H., Inohara, H., Kubo, T., and Tsujimoto, Y. (2005). Cyclophilin D-dependent
mitochondrial permeability transition regulates some necrotic but not
apoptotic cell death. Nature 434, 652–658.
Notarnicola, M., Messa, C., Pricci, M., Guerra, V., Altomare, D.F., Montemurro,
S., and Caruso, M.G. (2004). Up-regulation of 3-hydroxy-3-methylglutaryl
coenzyme A reductase activity in left-sided human colon cancer. Anticancer
Res. 24, 3837–3842.
Nowakowski, G.S., Maurer, M.J., Habermann, T.M., Ansell, S.M., Macon,
W.R., Ristow, K.M., Allmer, C., Slager, S.L., Witzig, T.E., and Cerhan, J.R.
(2010). Statin use and prognosis in patients with diffuse large B-cell lymphoma
and follicular lymphoma in the rituximab era. J. Clin. Oncol. 28, 412–417.
Parmigiani, G., Lin, J., Boca, J.S., Sjo¨blom, T., Jones, S., Wood, L.D., Parsons,
D.W., Barber, T., Buckhaults, P., Sanford, D.M., et al. (2007). Response to
Comments on ‘‘The Consensus Coding Sequences of Human Breast and
Colorectal Cancers’’. Science 317, 1500.
Pickeral, O.K., Li, J.Z., Barrow, I., Boguski, M.S., Maka1owski, W., and Zhang,
J. (2000). Classical oncogenes and tumor suppressor genes: a comparative
genomics perspective. Neoplasia 2, 280–286.
Poynter, J.N., Gruber, S.B., Higgins, P.D., Almog, R., Bonner, J.D., Rennert,
H.S., Low, M., Greenson, J.K., and Rennert, G. (2005). Statins and the risk
of colorectal cancer. N. Engl. J. Med. 352, 2184–2192.CelRepasky, G.A., Chenette, E.J., and Der, C.J. (2004). Renewing the conspiracy
theory debate: does Raf function alone to mediate Ras oncogenesis? Trends
Cell Biol. 14, 639–647.
Robertson, T.B., and Burnett, T.C. (1913). The influence of lecithin and choles-
terin upon the growth of tumours. J. Exp. Med. xvii, 344–352.
Rubin, A.F., and Green, P. (2007). Comment on ‘‘The consensus coding
sequences of human breast and colorectal cancers’’. Science 317, 1500.
Rudling, M., and Collins, V.P. (1996). Low density lipoprotein receptor and
3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordi-
nately reduced in human renal cell carcinoma. Biochim. Biophys. Acta 1299,
75–79.
Rust, S., Rosier, M., Funke, H., Real, J., Amoura, Z., Piette, J.C., Deleuze, J.F.,
Brewer, H.B., Duverger, N., Dene`fle, P., and Assmann, G. (1999). Tangier
disease is caused by mutations in the gene encoding ATP-binding cassette
transporter 1. Nat. Genet. 22, 352–355.
Schaffner, C.P. (1981). Prostatic cholesterol metabolism: regulation and alter-
ation. Prog. Clin. Biol. Res. 75A, 279–324.
Schimanski, S., Wild, P.J., Treeck, O., Horn, F., Sigruener, A., Rudolph, C.,
Blaszyk, H., Klinkhammer-Schalke, M., Ortmann, O., Hartmann, A., and
Schmitz, G. (2009). Expression of the lipid transporters ABCA3 and ABCA1
is diminished in human breast cancer tissue. Horm. Metab. Res. 42, 102–109.
Schlabach, M.R., Luo, J., Solimini, N.L., Hu, G., Xu, Q., Li, M.Z., Zhao, Z.,
Smogorzewska, A., Sowa, M.E., Ang, X.L., et al. (2008). Cancer proliferation
gene discovery through functional genomics. Science 319, 620–624.
Sewing, A., Wiseman, B., Lloyd, A.C., and Land, H. (1997). High-intensity
Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 17,
5588–5597.
Shaffer, A.L., Emre, N.C., Lamy, L., Ngo, V.N., Wright, G., Xiao, W., Powell, J.,
Dave, S., Yu, X., Zhao, H., et al. (2008). IRF4 addiction in multiple myeloma.
Nature 454, 226–231.
Shannon, J., Tewoderos, S., Garzotto, M., Beer, T.M., Derenick, R., Palma, A.,
and Farris, P.E. (2005). Statins and prostate cancer risk: a case-control study.
Am. J. Epidemiol. 162, 318–325.
Siddiqui, A.A., Nazario, H., Mahgoub, A., Patel, M., Cipher, D., and Spechler,
S.J. (2009). For patients with colorectal cancer, the long-term use of statins is
associated with better clinical outcomes. Dig. Dis. Sci. 54, 1307–1311.
Singaraja, R.R., Visscher, H., James, E.R., Chroni, A., Coutinho, J.M., Brun-
ham, L.R., Kang, M.H., Zannis, V.I., Chimini, G., and Hayden, M.R. (2006).
Specific mutations in ABCA1 have discrete effects on ABCA1 function and
lipid phenotypes both in vivo and in vitro. Circ. Res. 99, 389–397.
Siperstein, M.D. (1995). Cholesterol, cholesterogenesis and cancer. Adv. Exp.
Med. Biol. 369, 155–166.
Sjo¨blom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D.,
Mandelker, D., Leary, R.J., Ptak, J., Silliman, N., et al. (2006). The consensus
coding sequences of human breast and colorectal cancers. Science 314,
268–274.
Strasak, A.M., Pfeiffer, R.M., Brant, L.J., Rapp, K., Hilbe, W., Oberaigner, W.,
Lang, S., Borena, W., Concin, H., Diem, G., et al; VHM&PP Study Group.
(2009). Time-dependent association of total serum cholesterol and cancer
incidence in a cohort of 172,210 men and women: a prospective 19-year
follow-up study. Ann. Oncol. 20, 1113–1120.
Tabas, I. (2010). The role of endoplasmic reticulum stress in the progression of
atherosclerosis. Circ. Res. 107, 839–850.
Tatidis, L., Masquelier, M., and Vitols, S. (2002). Elevated uptake of low density
lipoprotein by drug resistant human leukemic cell lines. Biochem. Pharmacol.
63, 2169–2180.
Thibault, A., Samid, D., Tompkins, A.C., Figg, W.D., Cooper, M.R., Hohl, R.J.,
Trepel, J., Liang, B., Patronas, N., Venzon, D.J., et al. (1996). Phase I study of
lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Clin. Cancer Res. 2, 483–491.
Van Hemelrijck, M., Walldius, G., Jungner, I., Hammar, N., Garmo, H., Binda,
E., Hayday, A., Lambe, M., and Holmberg, L. (2011). Low levels ofl Reports 2, 580–590, September 27, 2012 ª2012 The Authors 589
apolipoprotein A-I and HDL are associated with risk of prostate cancer in the
Swedish AMORIS study. Cancer Causes Control 22, 1011–1019.
Warburg, O. (1930). The Metabolism of Tumors (London: Arnold Constable).
Weinberg, F., Hamanaka, R., Wheaton, W.W., Weinberg, S., Joseph, J.,
Lopez, M., Kalyanaraman, B., Mutlu, G.M., Budinger, G.R., and Chandel,
N.S. (2010). Mitochondrial metabolism and ROS generation are essential for
Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. USA 107, 8788–8793.
Whitehead, R.H., VanEeden, P.E., Noble, M.D., Ataliotis, P., and Jat, P.S.
(1993). Establishment of conditionally immortalized epithelial cell lines from
both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proc.
Natl. Acad. Sci. USA 90, 587–591.590 Cell Reports 2, 580–590, September 27, 2012 ª2012 The AuthorXia, M., and Land, H. (2007). Tumor suppressor p53 restricts Ras stimulation
of RhoA and cancer cell motility. Nat. Struct. Mol. Biol. 14, 215–223.
Yoshioka, Y., Sasaki, J., Yamamoto, M., Saitoh, K., Nakaya, S., and Kubo-
kawa, M. (2000). Quantitation by (1)H-NMR of dolichol, cholesterol and
choline-containing lipids in extracts of normal and phathological thyroid tissue.
NMR Biomed. 13, 377–383.
Zender, L., Xue,W., Zuber, J., Semighini, C.P., Krasnitz, A., Ma, B., Zender, P.,
Kubicka, S., Luk, J.M., Schirmacher, P., et al. (2008). An oncogenomics-
based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell
135, 852–864.s
